Related Experiment Videos
Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies.
Masahiro Kami1, Atsushi Makimoto, Yuji Heike
1Department of Medical Oncology, Hematopoietic Stem Cell Transplantation Unit, the National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan. mkami@ncc.go.jp
Japanese Journal of Clinical Oncology
|January 11, 2005
Summary
Reduced intensity stem cell transplantation (RIST) offers a new treatment option for elderly patients ineligible for conventional hematopoietic stem cell transplantation (HSCT). This approach shows reduced toxicity and improved short-term outcomes, with potential in solid tumors like renal cell carcinoma.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Reduced intensity stem cell transplantation (RIST) is an emerging approach offering an alternative to conventional myeloablative hematopoietic stem cell transplantation (HSCT).
- RIST expands treatment eligibility to elderly patients and those with comorbidities not suitable for traditional HSCT.
- Early phase studies indicate RIST's potential for reduced regimen-related toxicity and improved short-term prognoses compared to conventional HSCT.
Purpose of the Study:
- To review the current status and potential of Reduced Intensity Stem Cell Transplantation (RIST).
- To highlight RIST's efficacy in specific solid tumors, particularly metastatic renal cell carcinoma.
- To underscore the need for further research into the mechanisms of graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effects.
Main Methods:
- Review of Phase I and II clinical studies on Reduced Intensity Stem Cell Transplantation (RIST).
- Analysis of RIST's application in elderly patients and comparison with conventional hematopoietic stem cell transplantation (HSCT).
- Examination of RIST's efficacy in solid tumors, with a focus on metastatic renal cell carcinoma.
Main Results:
- RIST demonstrates promising features and is a viable option for patients previously ineligible for HSCT.
- RIST has shown reduced toxicity and better short-term outcomes compared to conventional HSCT.
- Metastatic renal cell carcinoma exhibits a positive response to RIST, with ongoing trials for other solid tumors.
Conclusions:
- RIST represents a significant advancement in stem cell transplantation, broadening treatment accessibility.
- Further investigation into the mechanisms of GVHD and GVT is critical for optimizing RIST's antitumor effects and patient prognosis.
- RIST holds promise for improving outcomes in various cancers, especially in patient populations not suited for conventional HSCT.